Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells

Vascular Pharmacology

Volumn 51, Issue 2-3, 2009, Pages 162-168

  Desouza, Cyrus V ^a,b   Gerety, Moira ^a,b   Hamel, Frederick G ^a,b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Endothelial regrowth; Insulin resistance; Neointimal hyperplasia; Pioglitazone; PPAR gamma

Indexed keywords

FIBROBLAST GROWTH FACTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PIOGLITAZONE; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; MOLECULAR MECHANICS; PRIORITY JOURNAL; UMBILICAL VEIN;

APOPTOSIS; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR GAMMA; THIAZOLIDINEDIONES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 68049132855     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.05.001     Document Type: Article

References (24)

1. Cohen M.H., Gootenberg J., Keegan P., and Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12 (2007) 713-718
2. Corros C., Jimenez-Quevedo P., and Sabate M. Diabetes mellitus and percutaneous coronary revascularization. Minerva Cardioangiol. 53 (2005) 431-443
3. Desouza C.V., Murthy S.N., Diez J., Dunne B., Matta A.S., Fonseca V.A., and McNamara D.B. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J. Cardiovasc. Pharmacol. Ther. 8 (2003) 297-305
4. Desouza C.V., Gerety M., and Hamel F.G. Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats. Atherosclerosis 184 (2006) 283-289
5. Desouza C.V., Gerety M., and Hamel F.G. Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Vasc. Pharmacol. 46 (2007) 188-194
6. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., and Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J. Am. Coll. Cardiol. 49 (2007) 1772-1780
7. Fang C.C., Ng Jao Y.T., Yi C., Yu C.L., Chen C.L., and Wang S.P. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. Angiology 58 (2007) 523-534
8. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs (2005) 209-231
9. Gray J.L., Kang S.S., Zenni G.C., Kim D.U., Kim P.I., Burgess W.H., Drohan W., Winkles J.A., Haudenschild C.C., and Greisler H.P. FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia. J. Surg. Res. 57 (1994) 596-612
10. Hedblad B., Zambanini A., Nilsson P., Janzon L., and Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J. Intern. Med. 261 (2007) 293-305
11. Hong Y., Jin X., Mo J., Lin H.M., Duan Y., Pu M., Wolbrette D.L., and Liao D. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J. Intern. Med. 262 (2007) 113-122
12. Kipshidze N., and Leon M.B. Endothelial dysfunction after drug-eluting stent was never predicted in preclinical studies. J. Am. Coll. Cardiol. 47 (2006) 1911 (author reply 1912-1913)
13. Klagsbrun M. Angiogenic factors: regulators of blood supply-side biology. FGF, endothelial cell growth factors and angiogenesis: a keystone symposium, Keystone, CO, USA, April 1-7, 1991. New Biol. 3 (1991) 745-749
14. Nakamura T., Mochizuki Y., Kanetake H., and Kanda S. Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem. Biophys. Res. Commun. 289 (2001) 801-806
15. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
16. Rajagopalan S., Shah M., Luciano A., Crystal R., and Nabel E.G. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 104 (2001) 753-755
17. Ratner M. Genentech discloses safety concerns over Avastin. Nat. Biotechnol. 22 (2004) 1198
18. Reidy M.A., Clowes A.W., and Schwartz S.M. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab. Invest. 49 (1983) 569-575
19. Riche D.M., and Dale K.M. A perspective on coronary revascularization in the PROactive 05 study. J. Am. Coll. Cardiol. 50 (2007) 1705-1706 author reply 1706
20. Scheen A.J. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular disease]. Rev. Med. Liege. 61 (2006) 728-732
21. Shoelson S.E., Herrero L., and Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007) 2169-2180
22. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
23. Van Belle E., Bauters C., Asahara T., and Isner J.M. Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovasc. Res. 38 (1998) 54-68
24. Versari D., Lerman L.O., and Lerman A. The importance of reendothelialization after arterial injury. Curr. Pharm. Des. 13 (2007) 1811-1824